We are registered as an independent intermediary for medicines with the Dutch Ministry of Health
Locally advanced or metastatic urothelial carcinoma
Mode of Action
PD-L1 blocking antibody (immunotherapy)
FDA approved (USA)
Who is durvalumab for?
Imfinzi (durvalumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
have disease progression during or following platinum-containing chemotherapy
have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy .
Complete information about durvalumab dosage and administration can be found here . The standard dosage is:
10 mg per kilogram of body weight as an intravenous infusion over 60 minutes every 2 weeks
Dilute prior to intravenous infusion.
Consult your doctor for personalised dosage.
What is durvalumab and how does it work?
Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody used to treat adults with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy . Durvalumab is a monoclonal antibody (a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody) — a type of protein that has been designed to recognise and attach to a specific structure, found in certain cells in the body. Durvalumab has been designed to attach to a receptor called PD-1, found on certain cells of the immune system called T cells. Cancer cells can produce proteins (PD-L1 and PD-L2) that attach to this receptor and, in this way, switch off the T cells. By attaching to the receptor, durvalumab prevents cancer cells from switching off T cells, thereby increasing the ability of the immune system to kill cancer cells .
for locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. The FDA also approved the VENTANA PD-L1 (SP263) Assay (Ventana Medical Systems, Inc.) as a complementary diagnostic for the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded urothelial carcinoma tissue . The approvals were based on a single-arm clinical trial involving 182 patients. The objective response rate (ORR) was 17.0 % (95 % CI: 11.9, 23.3) across the whole cohort; the ORR for patients with high PD-L1 score (95 patients) was 26.3 % (95 % CI: 17.8, 36.4); the ORR for patients with low or negative PD-L1 score (73 patients) was 4.1 % (95 % CI: 0.9, 11.5). The duration of response ranged between 0.9+ to 19.9+ months (median not reached) . The most common adverse reactions in at least 15 % of patients were fatigue, musculoskeletal pain, constipation, decreased appetite, nausea, peripheral edema, and urinary tract infection. Grade 3 to 4 adverse events were seen in 43 % of patients. Infection and immune-related adverse events such as pneumonitis, hepatitis, colitis, thyroid disease, adrenal insufficiency, and diabetes were also seen with durvalumab .
Buyer For EU individuals, VAT is 6% on medicines + 21% on shipping
Shipping Cost Estimate per order
VAT Tax can be claimed back by non-EU citizens on exiting the EU
Send this price estimate to your email address
Please complete the form, then try sending again.
*Once you provide us with the exact shipping address, the actual price may vary. After receiving the estimate, we may contact you to offer further assistance.
The more expensive medicines are patent-protected, and their prices are set by the pharmaceutical industry. We are constantly negotiating to get you best prices. As a social enterprise we only charge small fees to cover our operational costs.
Ordering with TheSocialMedwork is a safe and legal way to import a prescription medicine that has been approved in another country, but is not yet available where you live.
If you think that this medicine may be suitable for treating your condition, get in touch.
We'll answer any questions you might have and provide you with further information. Select the
Calculate Price tab to get a close estimate of the full cost of the medicine including delivery.
If you would like us to provide you with a precise quote we'll need to know the exact address of where you want us to send your medicine to.
2. Chat with your doctor
About whether this treatment might be suitable for you. In order to place an order with us, you’ll need to provide us with a prescription from your doctor who must be based in the same country where the medicine will be shipped to.
3. Place your order
Once you have your doctor's prescription you’re ready to place an order with us. Payment can be made by credit card, electronic bank transfer or Paypal.
As soon as we receive your payment we’ll process your order and your medicine will be shipped to you via a pharmacy.
Delivery time can vary from country to country but usually takes 1 to 3 weeks.
We'll send you a tracking number and keep you up to date on the status of your order.
Rest assured that we'll guide you through the entire process.
We'll let you know exactly what regulations need to be followed and the specific documentation you'll need to import the medicine into your country so that you get your treatment as quickly as possible. Ask us a question
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.
"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."
- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.
DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision.
Terms and Conditions